Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Nicolazzo, Chiara ^a   Raimondi, Cristina ^a   Mancini, Marialaura ^b   Caponnetto, Salvatore ^b   Gradilone, Angela ^a   Gandini, Orietta ^a   Mastromartino, Maria ^a   Del Bene, Gabriella ^b   Prete, Alessandra ^b   Longo, Flavia ^b   Cortesi, Enrico ^b   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; DISEASE EXACERBATION; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PROGNOSIS; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR EMBOLISM;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84983666703     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31726     Document Type: Article

References (22)

1. Dempsey, P. W., Vaidya, S. A. & Cheng, G. The art of war: Innate and adaptive immune responses. Cell Mol Life Sci. 60, 2604-2621 (2003).
2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 (2012).
3. Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 373(2), 123-135 (2015).
4. Patel, S. P. & Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 14, 847-856 (2015).
5. Meng, X., Huang, Z., Teng, F., Xing, L. & Yu, J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 41, 868-876 (2015).
6. Remon, J., Chaput, N. & Planchard, D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in non-small cell lung cancer. Curr Opin Oncol. 28, 122-129 (2016).
7. Buder, A., Tomuta, C. & Filipits, M. The potential of liquid biopsies. Curr Opin Oncol. 28, 130-134 (2016).
8. Chakravarti, N. & Prieto, V. G. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res. 4, 743-751 (2015).
9. Mazel, M. et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 9, 1773-1782 (2015).
10. Hanssen, A. et al. Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer Front Oncol. 5: 207, doi: 10. 3389/ fonc. 2015. 00207 (2015).
11. Hoos, A. Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 23, 47-52 (2012).
12. Ligthart, S. T. et al. Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. Plos One 8, e67148 (2013).
13. Xue, C. & Mc Closkey, T. W. CTC categorization: Subpopulations of CTCs and their potential clinical significance. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia.
14. Lou, Y. et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. pii: clincanres 1434, 2015 (2016).
15. Monteiro, I. D., Califano, R., Mountzios, G. & de Mello, R. A. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. Future Oncol. 12, 551-564 (2016).
16. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 373, 1627-1639 (2015).
17. Gettinger, S. N. et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer J Clin Oncol. 33, 2004-2012 (2015).
18. Carbognin, L. et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. Plos One 10, e0130142 (2015).
19. Zhou, Z. J., Zhan, P. & Song, Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 4, 203-208 (2015).
20. Verdeil, G., Fuertes Marraco, S. A., Murray, T. & Speiser, D. E. From T cell "exhaustion" to anti-cancer immunity. Biochim Biophys Acta. 1865, 49-57 (2016).
21. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. & Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99, 12293-12297 (2002)
22. Dong, Z. Y., Wu, S. P., Liao, R. Q., Huang, S. M. & Wu, Y. L. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol. doi: 10. 1007/s13277-016-4812-9 (2016)